The ability of SS18-SSX to engage Wnt signaling without resorting to Wnt ligands may have important therapeutic implications at it suggests that mere impairment of canonical Wnt signaling may not suffice to abrogate SS development. Here, SSX2 is linked to synovial sarcoma.